Browsing Tag
KMT2A
1 post
How Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia patients
Find out how Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia, transforming treatment and investor sentiment alike.